The analysis of the cfDNA NGS panel before treatment with larotrectinib revealed both TPM3::NTRK1 fusion and MDM2/CDK4 amplification (Fig 1), reliably reflecting the genetic alterations of the original pelvic tumor tissue. Here, TPM3 is linked to neoplasm.